Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
65 USD | +0.05% | +0.08% | +240.98% |
May. 10 | Alpine Immune Sciences, Vertex Pharmaceuticals Deal Crosses Another Milestone | MT |
May. 09 | Alpine Immune Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+240.98% | 4.46B | |
+9.36% | 114B | |
+11.38% | 104B | |
-13.75% | 22.41B | |
-1.05% | 22.28B | |
-5.29% | 19.07B | |
-38.29% | 18B | |
-3.79% | 17.89B | |
+7.68% | 14.28B | |
+34.43% | 12.55B |
- Stock Market
- Equities
- ALPN Stock
- News Alpine Immune Sciences, Inc.
- Wedbush Raises Alpine Immune Sciences' PT to $26 From $19 on Increased Confidence in Potential of Povetacicept in Immunoglobulin A Nephropathy, Maintains Outperform Rating